Supplementary Table. Relative COVID-19 Vaccine Effectiveness Against Laboratory-Confirmed COVID-19–Associated Hospitalizations and Critical Illness† Among Adults Aged ≥18 Years Who Received a Bivalent Vaccine Dose Compared With Adults Aged ≥18 Years Who Received Monovalent Doses Only, by Age Group and Immunocompromise Status — Seven States, September 2022–April 2023

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

Advanced Search
Custom Query

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners. As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.

i

Supplementary Table. Relative COVID-19 Vaccine Effectiveness Against Laboratory-Confirmed COVID-19–Associated Hospitalizations and Critical Illness† Among Adults Aged ≥18 Years Who Received a Bivalent Vaccine Dose Compared With Adults Aged ≥18 Years Who Received Monovalent Doses Only, by Age Group and Immunocompromise Status — Seven States, September 2022–April 2023

05/26/2023
By Centers for Disease Control and Prevention (U.S.)
Source: MMWR: Morbidity and Mortality Weekly Report 2023; v. 72, no. 21
Series: Weekly Report: Morbidity and Mortality Weekly Report (MMWR)

English

Details You May Also Like

Details:

Alternative Title:

Estimates of Bivalent MRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions —VISION Network, September 2022–April 2023: Supplementary Table. Relative COVID-19 Vaccine Effectiveness Against Laboratory-Confirmed COVID-19–Associated Hospitalizations and Critical Illness† Among Adults Aged ≥18 Years Who Received a Bivalent Vaccine Dose Compared With Adults Aged ≥18 Years Who Received Monovalent Doses Only, by Age Group and Immunocompromise Status — Seven States, September 2022–April 2023
Corporate Authors:

Centers for Disease Control and Prevention (U.S.)
Subjects:

[+]

Disease Notification Public Health Public Health Surveillance
Source:

MMWR: Morbidity and Mortality Weekly Report 2023; v. 72, no. 21
Series:

Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
ISSN:

0149-2195 (print);1545-861X (digital);
Document Type:

Journal Article
Place as Subject:

United States
Pages in Document:

1 pdf page
Volume:

72
Issue:

21
Collection(s):

Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:

[+]

urn:sha-512:91a69c1ccc14559d2bc0d066ea9c5927708dde4cefb2267c1199c05ab834022d5aa211652bb113b761522d7befb04a1d9812826f309ab44b6a645541a147cb1d
Download URL:

https://stacks.cdc.gov/view/cdc/128421/cdc_128421_DS1.pdf
File Type:

[PDF-154.21 KB]